Preclinical Cro services in
Obesity
With over 15 years of experience in anti-obesity drug profiling, Gubra provides unparalleled expertise to guide your research from start to finish. We harness our scientific knowledge and readily available diet-induced obesity (DIO) rodent models to deliver comprehensive preclinical research studies targeting obesity. Our services include efficacy and mode-of-action studies, supported by a robust suite of analytical endpoints such as energy expenditure, metabolic profiling, body composition, acute food intake monitoring, and biomarker analysis. With advanced techniques like adipose, muscle, and liver histology, whole-brain imaging, and RNAseq, we provide deep insights into anti-obesity drug mechanisms.
Why choose Gubra?
-
-
Expert scientific guidance in preclinical obesity research
-
DIO rodent models fed a high fat diet, ready-to-use for your study
-
Individually tailored efficacy studies, delivering actionable insights for IND-enabling studies
-
Whole-brain spatial biology to capture and analyze neural drug response
-
Consult with Marco Tozzi
Senior Scientist, Scientific Sales
Advance your obesity drug development with our extensive knowhow.
Comprehensive Models for Preclinical Research in Obesity
Benefit from Gubra’s unparalleled expertise in preclinical obesity research. Our widely used diet-induced obesity (DIO) mouse models, a standard in the field, are optimized to meet the diverse needs of anti-obesity drug studies. For additional flexibility, we also offer DIO rat models, providing robust options for evaluating therapeutic efficacy and mode of action. With a proven track record of profiling numerous drug candidates, we deliver comprehensive and actionable data through tailored in vivo study designs and industry-standard models.
Main Efficacy Study Offerings
Instant availability of
(DIO) mice models
Comprehensive
Treatment efficacy studies
Real-time
Food intake monitoring
Detailed
Muscle health analysis
Detailed
Body composition analysis
Complete
Energy expenditure testing
Accelerate your anti-obesity drug profiling
Animal Obesity Models Available
Humanized GLP-1R mouse model
-
- Specialized mouse strain with human GLP-1 receptors
- Ideal for preclinical small molecule drug discovery and characterization
- Has normal behavior and physiology for reproducible results and comparisons across experiments
- Obesity induced by high fat diet (HFD), resulting in adiposity and prediabetes as seen in the DIO models
Diet-Induced Obesity (DIO) Mouse and Rat Model
-
A comprehensive model for obesity and metabolic syndrome research
-
Induced by high fat diet (HFD), resulting in adiposity and prediabetes
-
Ready-to-Use at Gubra for immediate implementation
-
Extensive Standard of care benchmark
Lep ob/ob and Lep db/db Mice Model
-
Industry standard genetic obese mice with either the Lep ob/ob and Lep db/db mutations
-
An effective model for investigating obesity and type II diabetes
-
Exhibits marked insulin resistance and glucose intolerance
-
Maintains intact leptin receptor signalling for accurate research
Explore cardioprotective effects of your drug candidates
Dislipidemia and Atherosclerosis Models
DIO-LDLR-KO mouse
- Atherosclerosis mouse model
- Male LDLR-/- mice on western diet
- Dyslipidemia with hypercholesterolemia (LDL)
- Quantitative 3D imaging of plaque formation
- Quantitative 3D imaging of vascular inflammation
DIO-PCSK9-AAV mouse
- Atherosclerosis mouse model
- PCSK9-AAV in combination with WD
- Dyslipidemia/hypercholesterolemia in mice
- Quantitative 3D imaging of plaque formation
- Quantitative 3D imaging of vascular inflammation
Investigate your compound’s mode of action
Specialized Assays and Endpoints
Body Composition and Real-Time Food Intake
-
- Body composition determined via echoMRI to quantify lean and fat mass
- Detailed real time acute food/water intake and locomotor activity
- Treatment efficacy across a wide range of anti-obesity drug classes to determine appetite effects
- Screening up to 14 compounds/doses
- HM2 and PhenoMaster systems
Energy expenditure monitoring
- A multi-modular platform for carrying out metabolic, behavioral and physiological monitoring
- Detailed real time indirect calorimetry monitoring
- Ideal for acute and semi-chronic studies
- TSE system
Assay Add-ons
-
- Suitable for lean mice, DIO mice, and DIO rats
- Possibility to run obesity studies at thermoneutrality
- Muscle functionality readouts (i.e., grip strength, in vitro readout)
- Conditioned taste aversion (CTA) assay
- Glucose and insulin tolerance test (OGTT/ITT)
Additional Endpoints
-
- MSD analysis of inflammatory and obesity markers
- Liver and plasma biomarker assays
- TC/TG assay
- Histological and pathological scoring of fat, muscle, and liver tissues
- Whole organ imaging of brain, fat, and muscle
PROGRESS YOUR STUDY WITH GREATER CERTAINTY
High-resolution 3D whole-hindlimb imaging for quantitative muscle endpoints
Drug development for sarcopenic obesity requires multidimensional assessment of muscle structure, mass, and function. Gubra’s 3D imaging platform enables automated quantification of multiple histological endpoints in intact rodent hind limbs, integrated with in vivo metabolic and functional data to deliver robust, data-driven insights for your drug candidate.
Cloud-based data viewer
GubraView
Gubra’s cloud-based software, GubraView, provides instant, real-time access to study data as it is uploaded, ensuring seamless monitoring throughout your study. With features for cross-group and cross-study comparisons, GubraView enables informed decision-making with statistical analyses. Its integrated brain-viewer combines visual and quantitative data from whole-brain imaging, offering precise insights into cell counts and signal intensities. Accessible across multiple locations, GubraView empowers efficient and collaborative drug development for your whole team.
Progress your study with greater certainty
Whole-brain imaging of compound distribution and neural activation
To better understand biodistribution and altered activity in appetite-regulating brain regions, Gubra uses industry-leading spatial biology techniques to determine the distribution of fluorescently-tagged peptides and antibodies throughout the entire brain. This all-encompassing, IND-enabling approach ensures precise visualization of compound distribution, drug target mapping, and quantifiable treatment outcomes via quantification of a neural activation marker (c-Fos) providing deep insights for your preclinical candidate.
Related pages
For further information
Contact us
Gubra
Hørsholm Kongevej 11B
2970 Hørsholm
Denmark
+45 3152 2650